Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) and Incyte Corporation (Nasdaq: INCY) have announced positive topline results from the pivotal AGAVE-201 trial of axatilimab in chronic graft-versus-host disease (GVHD). The trial successfully met its primary endpoint, demonstrating an overall response rate (ORR) of 74% when administered at a dose of 0.3 mg/kg every two weeks. Furthermore, the data reve..